Protective Effect of Marine Peptides/Toxins in CVD Using Zebrafish Model

  • Saravanan Ramachandran
  • Senthilkumar Rajagopal


Diseases occurring in heart or blood vessels are known as cardiovascular diseases (CVDs). Myocardial infarction and angina are commonly known as heart attack, and they are also known as coronary artery diseases (CADs). Other CVDs include stroke, heart failure, hypertensive, rheumatic heart diseases, cardiomyopathy, heart arrhythmia, congenital heart disease, alular heart disease, carditis, aortic aneurysms, peripheral artery disease, thromboembolic disease and venous thrombosis. About 90% of CVDs are preventable. CVD can be prevented by good eating habit, regular exercise, avoiding tobacco and smoke and limited alcohol intake. The zebrafish (Danio rerio) is an excellent model for studies of CVD and CAD. Bioactive macromolecules derived from marine materials and biopeptides are enhance our health promotion and reduces diseases risk. This chapter reveals that marine peptides could be used as an antihypertensive agent, and that the zebrafish provides an alternative in vivo model to efficiently evaluate the antihypertensive properties of marine peptides.


Antihypertensive agent Coronary artery diseases Marine peptides Mediterranean diet Physical activity Statins 



The support provided by the Department of Biotechnology, Ministry of Science and Technology, Government of India (To Dr. Senthilkumar Rajagopal – No: BT/RLF/Reentry/42/2012) to complete this chapter in a successful manner is gratefully acknowledged.


  1. Ahmed H, Blaha M, Nasir K, Rivera J, Blumenthal R (2012) Effects of physical activity on cardiovascular disease. Am J Cardiol 109:288–295CrossRefGoogle Scholar
  2. Allen J, Neely M (2010) Trolling for the ideal model host: zebrafish take the bait. Future Microbiol 5:563–569CrossRefGoogle Scholar
  3. Ambrose J, Rajat S (2004) The pathophysiology of cigarette smoking and cardiovascular disease: an update. J Am Coll Cardiol 43:1731–1737CrossRefGoogle Scholar
  4. Aronson D (2008) Hyperglycemia and the pathobiology of diabetic complications. Adv Cardiol 45:1–16CrossRefGoogle Scholar
  5. Arun C, Duvoor C, Reddy Dendi V, Kraleti S, Chada A, Ravilla R, Marco A, Shekhawat N, Montales M, Kuriakose K, Sasapu A, Beebe A, Patil N, Musham C, Lohani G, Mirza W (2017) Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management. Front Endocrinol 8:6Google Scholar
  6. Barnes V, Orme-Johnson D (2012) Prevention and treatment of cardiovascular disease in adolescents and adults through the transcendental meditation® program: a research review update. Curr Hypertens Rep 8:227–242CrossRefGoogle Scholar
  7. Bruning R, Sturek M (2015) Benefits of exercise training on coronary blood flow in coronary artery disease patients. Prog Cardiovasc Dis 57:443–453CrossRefGoogle Scholar
  8. Chablais F, Jazwinska A (2012) The regenerative capacity of the zebrafish heart is dependent on TGFβ signaling. Dev Stem Cell 139:1921–1930Google Scholar
  9. Chae C, Albert C, I-Min L, Buring J (2012) Vitamin E supplementation and the risk of heart failure in women. Circ Heart Fail 5:176–182CrossRefGoogle Scholar
  10. Chiang N, Bermudez E, Ridker P, Hurwitz S, Serhan C (2004) Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. Proc Natl Acad Sci U S A 101:15178–15183CrossRefGoogle Scholar
  11. Cicero A, Fogacci F, Colletti A (2017) Potential role of bioactive peptides in prevention and treatment of chronic diseases: a narrative review. Br J Pharmacol 174:1378–1394CrossRefGoogle Scholar
  12. Cogswell M, Kristy M, Bowman B, Frieden T (2016) Dietary sodium and cardiovascular disease risk—measurement matters. N Engl J Med 375:580–586CrossRefGoogle Scholar
  13. Costa A, Reina-Couto M, Albino-Teixeira A, Sousa T (2017) Aspirin and blood pressure: effects when used alone or in combination with antihypertensive drugs. Rev Port Cardiol 36:551–567CrossRefGoogle Scholar
  14. Coutinho T, Al-Omari M, Mosley TJ, Kullo I (2011) Biomarkers of left ventricular hypertrophy and remodeling in blacks. Hypertension 58:920–925CrossRefGoogle Scholar
  15. Covassin N, Singh P (2017) Sleep duration and cardiovascular disease risk: epidemiologic and experimental evidence. Sleep Med Clin 11:81–89CrossRefGoogle Scholar
  16. David L, Samia R, Johansson P, Jaarsma T (2014) Depression and cardiovascular disease: a clinical review. Eur Heart J 35:1365–1372CrossRefGoogle Scholar
  17. Diaz K, Shimbo D (2013) Physical activity and the prevention of hypertension. Curr Hypertens Rep 15:659–668CrossRefGoogle Scholar
  18. Dietrich M, Jacques P, Pencina M, Lanier K, Keyes M, Kaur G, Wolf P, D’Agostino R, Vasan R (2009) Vitamin E supplement use and the incidence of cardiovascular disease and all-cause mortality in the Framingham Heart Study: does the underlying health status play a role? Atherosclerosis 205:549–553CrossRefGoogle Scholar
  19. Dimsdale J (2008) Psychological stress and cardiovascular disease. J Am Coll Cardiol 51:1237–1246CrossRefGoogle Scholar
  20. Ding Y, Liu X, Bu L, Li H, Zhang S (2012) Antimicrobial-immunomodulatory activities of zebrafish phosvitin-derived peptide Pt5. Peptides 37:309–313CrossRefGoogle Scholar
  21. Dooley K, Zon L (2000) Zebrafish: a model system for the study of human disease. Curr Opin Genet Dev 10:252–256CrossRefGoogle Scholar
  22. Drewnowski A (2009) Obesity, diets, and social inequalities. Nutr Rev 67:S36–S39CrossRefGoogle Scholar
  23. Fatemeh B, Hamed M, Reza C, Harlan B, Elisabetta P, Annalisa S, Mataleena P, Carlo P, Ashok A (2017) Zebrafish as a model organism for the development of drugs for skin cancer. Int J Mol Sci 18:1550CrossRefGoogle Scholar
  24. Fogelholm M (2010) Physical activity, fitness and fatness: relations to mortality, morbidity and disease risk factors: a systematic review. Obes Rev 11:202–221CrossRefGoogle Scholar
  25. Franzini Pereira R, Franz M (2008) Prevention and treatment of cardiovascular disease in people with diabetes through lifestyle modification: current evidence-based recommendations. Diabetes Spectr 21:189–193CrossRefGoogle Scholar
  26. Giulia C, Busnelli M, Manzini S, Parolini C (2016) Nutraceuticals and bioactive components from fish for dyslipidemia and cardiovascular risk reduction. Mar Drugs 14:113CrossRefGoogle Scholar
  27. Helmut G, Christoph W (2012) Magnesium in disease. Clin Kidney J 5:i25–i38CrossRefGoogle Scholar
  28. Hendry V, Almíron-Roig E, Monsivais P, Jebb S, Benjamin Neelon S, Griffin S, Ogilvie D (2015) Impact of regulatory interventions to reduce intake of artificial trans–fatty acids: a systematic review. Am J Public Health 105:e32–e42CrossRefGoogle Scholar
  29. Highlander P, Shaw G (2010) Current pharmacotherapeutic concepts for the treatment of cardiovascular disease in diabetics. Ther Adv Cardiovasc Dis 4:43–54CrossRefGoogle Scholar
  30. Hsu C, Wen Z, Lin C, Chakraborty C (2007) The zebrafish model: use in studying cellular mechanism for a spectrum of clinical disease entities. Curr Neurovasc Res 4:111–120CrossRefGoogle Scholar
  31. Ida-Johanne J, Mæhre H (2016) Preclinical and clinical studies on antioxidative, antihypertensive and cardioprotective effect of marine proteins and peptides—a review. Mar Drugs 14:211CrossRefGoogle Scholar
  32. Inoue T (2004) Cigarette smoking as a risk factor of coronary artery disease and its effects on platelet function. Tob Induc Dis 2:2CrossRefGoogle Scholar
  33. Jarari N, Rao N, Peela J, Ellafi K, Shakila S, Said A, Nelapalli N, Min Y, Darli Tun K, Jamallulail S, Rawal A, Ramanujam R, Naidu Yedla R, Kandregula D, Argi A, Teja Peela L (2016) A review on prescribing patterns of antihypertensive drugs. Clin Hypertens 22:7CrossRefGoogle Scholar
  34. Jing Y, Hai-Peng W, Ling-Mei Z, Zhou L, Chen T, Li-Qiang Q (2015) Effect of conjugated linoleic acid on blood pressure: a meta-analysis of randomized, double-blind placebo-controlled trials. Lipids Health Dis 14:11CrossRefGoogle Scholar
  35. Jingkai W, Rooks C, Ramadan R, Shah A, Bremner J, Quyyumi A, Kutner M, Vaccarino V (2014) Meta-analysis of mental stress–induced myocardial ischemia and subsequent cardiac events in patients with coronary artery disease. Am J Cardiol 114:187–192CrossRefGoogle Scholar
  36. Kannel W (1996) Blood pressure as a cardiovascular risk factor: prevention and treatment. J Am Med Assoc 275:1571–1576CrossRefGoogle Scholar
  37. Katayama S, Hatano M, Issiki M (2018) Clinical features and therapeutic perspectives on hypertension in diabetics. Hypertens Res 41:213–229CrossRefGoogle Scholar
  38. Katherine E, Maiorino M, Giuseppe B, Chiodini P, Panagiotakos D, Giugliano D (2015) A journey into a Mediterranean diet and type 2 diabetes: a systematic review with meta-analyses. BMJ Open 5:e008222CrossRefGoogle Scholar
  39. Kathryn I, Sheridan E, Grierson A (2018) Use of zebrafish models to investigate rare human diseas. J Med Genet 55:641–649CrossRefGoogle Scholar
  40. Kotchen T (2010) The search for strategies to control hypertension. Hypertension 122:1141–1143Google Scholar
  41. Kris-Etherton P, Harris W, Appel L (2002) American Heart Association Nutrition Committee. fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 106:2747–2757CrossRefGoogle Scholar
  42. Lavie C, Milani R, Ventura HJACCM (2009) Obesity and cardiovascular disease: risk factor, paradox and impact of weight loss. J Am Coll Cardiol 53:1925–1932CrossRefGoogle Scholar
  43. Li Y, Rosenblit P (2018) Glucagon-like peptide-1 receptor agonists and cardiovascular risk reduction in type 2 diabetes mellitus: is it a class effect? Curr Cardiol Rep 20:113CrossRefGoogle Scholar
  44. Logue J, AL-Ghibiwi H, Alamri A, Preiss D (2015) Systematic review of studies exploring reasons for statin non-adherence and of randomised controlled trials of interventions to improve adherence. Atherosclerosis 241:e52CrossRefGoogle Scholar
  45. Lui GK, Fernandes S, McElhinnery DB (2014) Managment of cardiovascular risk factors in adults with congenital heart disease. J Am Heart Assoc 3(6):1–9CrossRefGoogle Scholar
  46. Mainous A, Diaz V, Koopman R, Everett C (2005) Having a regular physician and attempted weight loss after screening for hypertension or hypercholesterolemia. Int J Obes (London) 29:223–227CrossRefGoogle Scholar
  47. McCluskey B, Postlethwait J (2015) Phylogeny of zebrafish, a “model species,” within Danio, a “model genus”. Mol Biol Evol 32:635–652CrossRefGoogle Scholar
  48. Meeker N, Trede N (2008) Immunology and zebrafish: spawning new models of human disease. Dev Comp Immunol 32:745–757CrossRefGoogle Scholar
  49. Morash M, Douglas S, Robotham A, Ridley C, Gallant J, Soanes K (2011) The zebrafish embryo as a tool for screening and characterizing pleurocidin host-defense peptides as anti-cancer agents. Dis Models Mech 4:622–633CrossRefGoogle Scholar
  50. Murphy G, McAlister F, Weir D, Tjosvold L, Eurich D (2014) Cardiovascular medication utilization and adherence among adults living in rural and urban areas: a systematic review and meta-analysis. BMC Public Health 14:544CrossRefGoogle Scholar
  51. Paola B, Elena B, Elisa D, Silvio B (2016) Supplementation with omega-3 fatty acids in psychiatric disorders: a review of literature data. J Clin Med 5:67CrossRefGoogle Scholar
  52. Pinto I, Martins D (2017) Prevalence and risk factors of arterial hypertension: a literature review. J Cardiovasc Med Ther 1:1–7Google Scholar
  53. Ramkumar S, Raghunath A, Raghunath S (2016) Statin therapy: review of safety and potential side effects. Acta Cardiol Singapore 33:631–639Google Scholar
  54. Rennekamp A, Peterson R (2015) 15 years of zebrafish chemical screening. Curr Opin Chem Biol 24:58–70CrossRefGoogle Scholar
  55. Richard E, Couri D (2011) Left ventricular hypertrophy: major risk factor in patients with hypertension: update and practical clinical applications. Int J Hypertens 2011:495349Google Scholar
  56. Richard Hobbs F (2015) Prevention of cardiovascular diseases. BMC Med 13:261CrossRefGoogle Scholar
  57. Sharma D, Asirvatham A, Singh P (2017) Dose modification of antidiabetic agents in patients with type 2 diabetes mellitus and heart failure. Indian J Endocrinol Metab 21:618–629CrossRefGoogle Scholar
  58. Shiroma E, I-Min L (2010) Physical activity and cardiovascular health: lessons learned from epidemiological studies across age, gender, and race/ethnicity. Circulation 122:743–752CrossRefGoogle Scholar
  59. Siri-Tarino Patty W, Qi S, Hu Frank B, Krauss Ronald M (2010) Saturated fat, carbohydrate, and cardiovascular disease. Am J Clin Nutr 91:502–509CrossRefGoogle Scholar
  60. Skerrett P, Willett W (2010) Essentials of healthy eating: a guide. J Midwifrey Womens Health 55:492–501CrossRefGoogle Scholar
  61. Steptoe A, Kivimäki M (2012) Stress and cardiovascular disease. Nat Rev Cardiol 9:360–370CrossRefGoogle Scholar
  62. Strike P, Steptoe A (2003) Systematic review of mental stress-induced myocardial ischaemia. Eur Heart J 24:690–703CrossRefGoogle Scholar
  63. Tang G, Meng X, Li Y, Zhao C, Liu Q, Li H (2017) Effects of vegetables on cardiovascular diseases and related mechanisms. Nutrients 9:E857CrossRefGoogle Scholar
  64. Trede N, Langenau D, Traver D, Look A, Zon L (2004) The use of zebrafish to understand immunity. Immunity 20:367–379CrossRefGoogle Scholar
  65. Van Gaal L, Mertens I, De Block C (2006) Mechanisms linking obesity with cardiovascular disease. Nature 444:875–880CrossRefGoogle Scholar
  66. Voelter-Mahlknecht S (2016) Epigenetic associations in relation to cardiovascular prevention and therapeutics. Clin Epigenetics 8:4CrossRefGoogle Scholar
  67. Wallace M, Ricco J, Barrett B (2014) Screening strategies for cardiovascular disease in asymptomatic adults. Prim Care 41:371–397CrossRefGoogle Scholar
  68. Wang M, Li L, Guo Q, Zhang S, Ji D, Li H (2016) Identification and expression of a new Ly6 gene cluster in zebrafish Danio rerio, with implications of being involved in embryonic immunity. Fish Shellfish Immunol 54:230–240CrossRefGoogle Scholar
  69. Wang H, Yuanyuan C, Yang X, Zhiyi M, Fan Y, Xining L, Ningling S (2017) Aspirin usage in patients with essential hypertension. BMJ Heart 97:A203Google Scholar
  70. Xinhua Q, Jin F, Hao Y, Li H, Tang T, Wang H, Yan W, Dai K (2013) Magnesium and the risk of cardiovascular events: a meta-analysis of prospective cohort studies. PLoS One 8:e57720CrossRefGoogle Scholar
  71. Yadav Y (2007) Exercise in the management of coronary artery disease. Med J Armed Forces India 63:357–361CrossRefGoogle Scholar
  72. Yano Y, Kario K (2012) Nocturnal blood pressure and cardiovascular disease: a review of recent advances. Hypertens Res 35:695–701CrossRefGoogle Scholar
  73. Zhao C, Meng X, Li Y, Li S, Liu Q, Tang G, Li H (2017) Fruits for prevention and treatment of cardiovascular diseases. Nutrients 9:E598CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Saravanan Ramachandran
    • 1
  • Senthilkumar Rajagopal
    • 2
  1. 1.Native Medicine and Marine Pharmacology Laboratory, Faculty of Allied Health SciencesChettinad Hospital and Research Institute, Chettinad Academy of Research and Education (Deemed to be a University)KelambakkamIndia
  2. 2.Department of BiochemistryRayalaseema UniversityKurnoolIndia

Personalised recommendations